In order to compare the effect of 3,5,3 0 -triiodothyroacetic acid (TRIAC) with those of triiodothyronine (T 3 ) and thyroxine (T 4 ), severely hypothyroid rats (n ¼ 56) were infused over 13 days with 1, 2 or 4 nmol/100 g body weight (BW) per day of T 3 or 2, 4 or 8 nmol/100 g BW per day of T 4 or TRIAC. The 8 nmol/100 g BW per day of T 4 or TRIAC induced the same increase in resting metabolic rate, yet 4 nmol/100 g BW per day of T 3 was more potent (P < 0.05). For inhibiting serum TSH levels, 2 nmol/100 g BW per day of TRIAC were significantly less active than 2 nmol/100 g BW per day of T 4 or 1 nmol/100 g BW per day of T 3 (TRIAC, serum TSH 35.5 Ϯ 5.7; T 3 2.58 Ϯ0.91; T 4 2.12 Ϯ0 .59 ng/ml). At higher doses serum TSH and b-TSH mRNA were unmeasurable.
Introduction

3,5,3
0 -Triiodothyroacetic acid (TRIAC) is assumed to be of therapeutic interest, since it has been postulated to have less peripheral effects than thyroxine (T 4 ) and triiodothyronine (T 3 ) and may therefore be used advantageously for thyrotropin (TSH) suppressive therapy in goitrous patients and in some cases with thyroid cancer (1, 2) . It has also been used in thyroid hormone resistance and there is controversy as to its therapeutic advantage for this indication (3, 4) . Recently two clinical investigations have been published with differing conclusions. Sherman & Ladenson (5) showed that TRIAC has a more pronounced effect on hepatic parameters such as sex hormone binding globulin and serum cholesterol levels than T 4 and we showed that TRIAC was more effective in inhibiting TSH secretion than stimulating basal and sleeping metabolic rate (6) . We also found a slightly better inhibition of serum TSH with TRIAC than with T 4 . However, the effect on serum TSH was short-lived and therefore three or four daily doses were necessary to extend the effect over 24 h. This represents a limitation for its therapeutic use. These studies were complemented recently in rats where the decay of the effects of TRIAC and T 4 after stopping treatment was studied (7) .
It became clear that conclusive comparisons between TRIAC and T 4 and T 3 could only be obtained if halflives would not influence the experiments. Therefore we chose to study these hormones under constant and long-lasting infusion where one can assume not only that the hormones had achieved a kinetic equilibrium but that their effects had also reached a maximum.
Materials and methods
3,3
0 -Diiodothyronine (3,3 0 -T 2 ), 3,5-diiodothyroacetic acid (3,5-Diac), 3, 5, 3 0 -triiodothyroacetic acid (TRIAC), 
Experimental procedures
Fifty-six rats weighing 120-150 g each were rendered hypothyroid by injection of 0.5 mCi [ 131 I]NaI/100 g BW. One week later, and throughout the whole experiment, MMI (200 mg/l) was added to the drinking water. Before implanting the minipumps, serum T 4 levels were determined by obtaining tail blood. In all rats except the euthyroid animals, the minipumps were implanted 6 weeks after the [ 131 I]NaI injection. The infusion rates at the time of implantation for TRIAC and T 4 were 2, 4 and 8 nmol/100 g BW per day, and for T 3 1, 2 and 4 nmol/100 g BW per day. The plasma metabolic clearance rate (MCR: infusion rate (per 100 g/h)/serum concentration) of each hormone was corrected by the changes in BW at the end of experiment.
Rats were decapitated, organs and sera collected and frozen in liquid nitrogen, then stored at ¹80 ЊC until required.
Resting metabolic rates (RMR)
RMR was only measured with the highest dose of either hormone by an open-circuit calorimeter equipped with a sensitive mass flowmeter before implantation and 6 and 13 days later (8) . RMR in the euthyroid litter mates were measured when they weighed the same as the hypothyroid rats at the moment of implantation (weight-matched). The measurement was repeated at the end of the experiment (age-matched).
Radioimmunoassays
Serum T 4 , T 3 and TRIAC levels were measured with published in-house RIAs, their intra-and inter-assay coefficients of variation ranging from 6 to 10%. The TRIAC radioimmunoassay was done with TRIAC standards, 125 I[TRIAC] and the T 3 antiserum. Serum TSH measurements were performed with reagents kindly provided by the National Institutes of Health (NIH, Bethesda, MD, USA). The detection limits were 0.1 pmol T 3 /ml, 0.3 pmol TRIAC/ml, 3 pmol T 4 /ml and 0.8 ng TSH/ml. 
Deiodination assays and protein measurements
Total RNA extraction and Northern blot hybridization
The total RNAs from liver, kidney and pituitary were extracted using the guanidinium thiocyanate method (12) . Aliquots of total RNA (20 mg) were denatured and subjected to electrophoresis through 1% agarose. The RNA was transferred to nylon membrane (Nytran-N, Schleicher and Schuell, Dassel, Germany) under vacuum using a VacuGene device (Pharmacia LKB Biotechnology, Uppsala, Sweden). The RNA quality and loading was controlled by ethidium bromide staining. The membranes were baked in an 80 ЊC oven for 2 h to fix RNA. Probes for rat malic enzyme (Me), 5 0 D1, b-TSH and growth hormone (GH) (kindly provided by Dr V M Nikodem from Clinical Endocrinology Branch, NIH, Dr P R Larsen from Harvard Medical School, Boston, MA, Dr F Carr from the Walter Reed Army Medical Centre, Washington DC, and Dr F DeNoto, University of California, San Francisco, CA, USA, respectively) were labeled with a-[ 32 P]dCTP using a random oligonucleotide priming kit (T7QuickPrimeTM, Pharmacia) to a specific activity of approximately 1 × 10 9 c.p.m./mg DNA (13) . After 4 h of prehybridization at 42 ЊC in 50% formamide, 0.5% SDS, 5 × SSC, 5 × Denhardt's solution and 100 g/ml denatured salmon sperm DNA, 32 Plabeled cDNA probe (1 × 10 6 c.p.m./ml) was added and hybridization was carried out overnight at the same temperature. Blots were washed twice at room temperature in 2 × SSC, 0.1% SDS for 15 min, once at 42 ЊC in 0.2 × SSC, 0.1% SDS for 10 min and afterwards at 65 ЊC in 0.2 × SSC, 0.1% SDS for 10 min. The membranes were exposed on a phosphor screen cassette and the amount of each mRNA was quantitated by scanning laser densitometry (Molecular Dynamics, Sunnyvale, CA, USA). Each membrane contained RNA samples from 2 nmol T 4 per day/100 g BW treated rats as controls.
Statistical methods
ANOVA with the Neuman-Keuls test was used when all 11 groups of rats were compared. A two-way ANOVA was used to study the effects of treatment and dose (ratio) and their interaction. The three treatments were the infusions of T 4 , T 3 and TRIAC. The dose effect was analyzed at three levels of ratio to the lowest dose (i.e. 1, 2 and 4). In addition, data from rats treated with T 3 or T 4 were compared by analysis of covariance, using serum T 3 values as the covariate. This analysis tests for the equality of the slopes of regression for the two treatments and the adjusted values were then used to compare the two treatment groups (T 3 rats vs T 4 rats). Since the T 4 treatment appeared to be the major cause of strong interaction in the ANOVA, we reanalyzed the data with only the two treatments, T 3 and TRIAC. Significance was considered as P < 0.05. Data are expressed as means Ϯ S.E.M.
Results
Effect on the body weight gain, heart to BW ratio and RMR
BW was equal in all hypothyroid rats before treatment (208 Ϯ 15 g). The increase in BW in thyroid hormone treated rats was 52 Ϯ 4.5 g and was independent of the type of hormone or dosage. Euthyroid age-matched rats were significantly heavier than the hypothyroid and treated rats (346 Ϯ 6.5 g). The ratio of heart to BW showed a dose-dependent increase. However, 8 nmol/ 100 g BW per day of TRIAC were needed to obtain a similar heart to BW ratio as in euthyroid rats while the same effect was obtained with 2 nmol T 4 or 1 nmol T 3 / 100 g BW per day. RMR was only measured with the highest dose. The RMR with 4 nmol/100 g BW per day of T 3 was significantly higher than for 8 nmol/100 g BW per day of T 4 and TRIAC, while there was no significant difference between TRIAC and T 4 ( Table 1) .
Serum thyroid hormone and TSH levels
Serum T 4 levels before implantation were less than 3 pmol/ml. Under the infusions of different concentration of T 3 , T 4 or TRIAC the respective serum concentrations increased. The increase was not linear, reflecting a dose-dependent increase of MCR. T 4 levels under 2 nmol T 4 /100 g BW per day were slightly higher than in agematched euthyroid rats (80.2 Ϯ 7.3 vs 69.5 Ϯ 1.4 pmol T 4 /ml; P < 0.05); but the serum T 3 levels were still significantly lower than euthyroid controls, confirming the role of the intact thyroid in T 3 secretion. With an infusion of 1 nmol T 3 /100 g BW per day, the T 3 levels were slightly but insignificantly higher than in agematched euthyroid rats (P < 0.05) ( Table 1) .
Serum TSH levels show important differences between the treated groups. Serum TSH levels with 2 nmol TRIAC/100 g BW per day were markedly increased (35.5 Ϯ 5.7 ng/ml) while for 2 nmol/100 g BW per day T 4 and 1 nmol T 3 , they were less than 0 .8 ng/ml (Table 1, P < 0.001). There was however no significant difference between the medium dose of TRIAC (1.4 Ϯ 0.26 ng TSH/ml for 4 nmol/100 g per day) and the lowest dose of T 4 or T 3 mentioned above. Unmeasurable serum TSH levels were found in rats treated with 2 and 4 nmol/100 g BW per day T 3 , 4 and 8 nmol/100 g BW per day T 4 , and 8 nmol of TRIAC/ 100 g BW per day. On a molar basis TRIAC was at least four times less active than T 3 and two times less than T 4 .
Peripheral effects of thyroid hormones
In this case the effects of increasing doses were stimulatory and allowed a comparison of the doseresponse curves. In order to make the comparison between the incremental effects of the hormones easier, the dose ratios were also compared. These were for all three hormones 1 : 2 : 4.
In order to study the T 3 -and T 4 -infused rats, analysis of covariance was performed, serum T 3 being the covariate. The slopes for heart and hepatic 5 0 D1 activity and Me mRNA vs serum T 3 were parallel for T 4 and T 3 treated rats (Figs 1, 2 and 3 ). For heart 5 0 D1 activity and Me mRNA the adjusted mean values of the activities were not significantly different, in other words, if serum T 3 is taken as covariate, the effects of T 4 and T 3 are identical. For hepatic 5 0 D1 activity, the adjusted means in T 4 treated rats were significantly greater then in T 3 treated rats (P < 0.001). Hence, for the same serum T 3 levels, T 4 treatment was 1.4 times more active than T 3 (Fig. 3) .
The comparison of T 3 and TRIAC effects on heart 5 0 D1 activity by two-way ANOVA showed a significant interaction between ratio level and treatment. The difference between the two treatments (P < 0.001) increased with higher doses and the incremental effect for increasing doses of TRIAC was much weaker than for T 3 (Fig. 4) . These results are in full agreement with the small effect of TRIAC on heart weight.
The two hepatic parameters, 5 0 D1 mRNA levels and enzyme activity and Me mRNA levels responded similarly to T 3 and TRIAC treatments since the incremental effects of increasing T 3 or TRIAC infusions were parallel. For 5 0 D1 mRNA and Me mRNA levels, T 3 was on a molar basis approximately twice as active as TRIAC (Figs 5 and 6 ). 5 0 D2 activity in brain cortex of hypothyroid rats was six times higher than in the age-matched euthyroid rats. With 2 nmol T 4 /100 g BW per day, the activity was significantly decreased and represented 50% of the one in euthyroid animals. With 8 nmol T 4 /100 g BW per day, 5 0 D2 activity was no longer measurable (Fig. 7) . In T 3 treated animals, the 5 0 D2 activity was significantly lower than in hypothyroid rats and 3-to 4-fold higher than in age-matched euthyroid rats. There was no dosedependency. Interestingly, TRIAC had no effect at all on 5 0 D2 activity. In hypothyroid animals brain 5 0 D3 activity was markedly decreased compared with the age-matched euthyroid rats. There was a highly significant difference between the three treatments and a significant interaction between the treatment and doses, indicating that all three hormones have different effects. T 4 was strongly stimulating 5 0 D3 activity (Fig. 8) . With 2 nmol T 4 /100 g BW per day, the activity was already significantly higher than in the age-matched euthyroid rats (P < 0.05). The increase was dose-dependent. Treatment with T 3 had only a minor effect on the 5 0 D3 activity. TRIAC was more potent than T 3 (P < 0.05) but less potent than T 4 (P < 0.05).
GH and b-TSH mRNA levels
The effect of three hormones on growth hormone mRNA levels are shown in Fig. 9 . GH mRNA was unmeasurable in hypothyroid animals and markedly stimulated by all three hormones. There was no clear dose-dependency.
b-TSH mRNA levels were detectable under 2 nmol TRIAC/100 g BW per day. They were not measurable with higher TRIAC doses and in all groups treated with either T 4 or T 3 (data not shown).
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Organ-specific effects of TRIAC in rats 541 Figure 3 The effect of T 3 and T 4 on hepatic 5 0 D1. The dose and treatment effects of T 3 and T 4 are very similar even though T 4 is slightly but significantly more potent than T 3 (140%).
Figure 4
Since T 3 and T 4 had identical effects on cardiac 5 0 D1 activity, the effect of TRIAC was only compared with T 3 . There is a marked difference between the type of treatment and the effect of increasing doses, TRIAC being a much weaker stimulator than T 3 (P < 0.001). In order to be able to compare the two treatments the molar ratios of the infusions (1:2:4) and not the absolute concentrations of infused hormones are given on the abscissa. As an example, 1 corresponds to 1 nmol/100 g BW per day of T 3 and 2 nmol/100 g BW per day of TRIAC. 
Discussion
Despite circumstantial evidence for some qualitative differences between T 3 and TRIAC (14-16), a good in vivo comparison of the effects of these similar thyroid hormones has been hampered by their different half-lives. To overcome this limitation we decided to infuse these hormones over a very long period of time insuring a kinetic equilibrium and a constant effect. In addition, T 4 was also studied since it is thought to play a special role in inhibiting 5 0 D2 activity and might be crucial for the inhibition of serum TSH. Also, it is postulated that for certain organs such as heart and liver the intracellularly produced T 3 is in free exchange with serum T 3 . For these organs, the serum T 3 concentrations under T 4 or T 3 treatment should correlate with the thyroid hormone effects.
This was in fact so since analysis of covariance clearly showed that there was no difference in the T 3 or T 4 effect on cardiac and hepatic 5 0 D1 activity as well as on Me mRNA levels. There was however a slightly higher activity of T 4 on hepatic 5 0 D1 activity. This cannot be easily explained but might indicate a small preferential intrahepatic conversion of T 4 to T 3 which would not be sufficient to affect the mRNA levels. More importantly, the results for the dose ratios of T 3 and TRIAC on Me mRNA levels and hepatic 5 0 D1 activity strongly suggest that for the two liver parameters the two hormones act identically even though in molar terms TRIAC had at least half the activity of T 3 and was as equally potent as T 4 . In an earlier study, TRIAC was found to be less active than T 4 and T 3 despite similar or better affinities for the T 3 receptors (17). Such differences were explained by the more rapid MCR of TRIAC so that after single injections of TRIAC the occupancy of the nuclear receptors was only short lived. With continuous infusions, the MCR can be calculated more accurately and unexpectedly no difference between the MCR of T 3 and TRIAC could be found. Therefore, the MCR cannot explain the molar ratio and we suggest differences in intracellular metabolism and/or differences in cellular and nuclear uptake of the two hormones. In this respect, recent work indicates that TRIAC is a superior substrate for sulfation and consequent deiodination than T 3 , while for cellular or nuclear uptake, contradictory results have been reported (18) (19) (20) (21) (22) .
TSH secretion is assumed to be controlled by at least two thyroid hormone related mechanisms: the role of the local conversion of T 4 to T 3 and the abundance of b1, b2 and possibly a1 T 3 receptors. TRIAC has a higher affinity for these receptors than T 3 yet the role of local conversion is probably more important and may partly explain the relative lower potency of TRIAC for TSH inhibition than T 4 (15) . It cannot explain, however, the difference with T 3 . These results are also in opposition to human studies where TRIAC seems to be slightly better than T 4 for inhibiting serum TSH (4) . It is also interesting to note that T 4 was not a preferential inhibitor of TSH compared with T 3 which has been postulated on the basis of its specific intrapituitary conversion to T 3 .
The most interesting findings are the difference between TRIAC and T 3 on heart to BW ratio and deiodinase. We hypothesize that the small increase of heart weight with increasing doses of TRIAC attest for a generalized difference of action between the two hormones, the 5 0 D1 activity being only one example. Even for T 4 for which there was no major difference in molar ratio with TRIAC, heart weight increased more than with TRIAC. It is well known that hyperthyroidism can induce cardiac hypertrophy and the RMR is an expression of the hyperthyroid state of the animals. Nevertheless, one does not find a difference between RMR of 8 nmol per day of T 4 or TRIAC, the only other parameter responding less well to TRIAC than to T 4 or T 3 is serum TSH. These findings suppose a specific difference of action for TRIAC on heart and in view of the clinical importance of cardiac effects of these hormones during TSH suppressive therapy further work on this topic will be necessary.
